Has the FDA inspected Empower Pharmacy? Inspection and warning letter records

Has the FDA inspected Empower Pharmacy?

Yes. FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists 2 entries for Empower Pharmacy: a 503B outsourcing facility in Houston, TX and a 503A pharmacy in Houston, TX, with 7 Form 483s issued from 2020 to Nov 14, 2025 and warning letters dated Oct 15, 2021, Apr 2, 2025 and Sep 18, 2026. FDA’s registered outsourcing facility list (updated Nov 6, 2026) names Empower Clinic Services New Jersey in East Windsor, NJ (not yet inspected) and Empower Pharma in Houston, TX (last inspected Nov 14, 2025, Form 483 issued, action “Response Letter Issued 6/3/2026”).

A Form 483 lists an investigator’s observations and is not a final FDA determination. These records cover all of the facility’s compounding, not only GLP-1 drugs.

Empower Clinic Services, LLC, (dba Empower Pharmacy), Houston, TX (503B)

FDA’s compounding inspections and actions page lists 9 actions for this entry.

Document
Nov 14, 2025Form 483483 Issued 11/14/2025fda.gov
Apr 2, 2025Warning letterWarning Letter Issued 04/02/2025FDA copy (archived)
Aug 28, 2024Form 483483 Issued 08/28/2024FDA copy (archived)
May 4, 2023Regulatory meetingRegulatory Meeting Held 05/04/2023Not linked by FDA
Aug 5, 2022Form 483483 Issued 08/05/2022FDA copy (archived)
Oct 15, 2021Warning letterWarning Letter (10/15/2021)FDA copy (archived)
Mar 6, 2020Form 483483 Issued 03/06/2020FDA copy (archived)
Jul 22, 2019Untitled letterUntitled Letter Issued 07/22/2019FDA copy (archived)
Apr 2, 2019FMD-145 letterFMD-145 Letter Issued 04/02/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

Empower Clinic Services, LLC, (dba Empower Pharmacy), Houston, TX (503A)

FDA’s compounding inspections and actions page lists 5 actions for this entry.

Document
Sep 18, 2026Warning letterWarning Letter Issued 09/18/2026fda.gov
Nov 14, 2025Form 483483 Issued 11/14/2025fda.gov
Apr 2, 2025Warning letterWarning Letter Issued 04/02/2025fda.gov
Oct 4, 2024Form 483483 Issued 10/04/2024FDA copy (archived)
Dec 1, 2023Form 483483 Issued 12/01/2023FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

On FDA’s registered 503B list

GLP-1 warning letters and recalls under this name

Empower Clinic Services, LLC dba Empower Pharmacy: 1 GLP-1 warning letter, 0 recall reports.

Later letters FDA listsLetter
Sep 18, 2026Empower Clinic Services, LLC dba Empower PharmacyCGMP/Finished Pharmaceuticals/Adulterated/Unapproved New DrugSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

These records share a name. FDA lists each under its own legal name and address, and the records do not say how the entities are related.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.